FY2025 Earnings Forecast for ENTA Issued By Leerink Partnrs

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Stock analysts at Leerink Partnrs upped their FY2025 EPS estimates for Enanta Pharmaceuticals in a research note issued on Monday, December 9th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings of ($4.70) per share for the year, up from their prior estimate of ($4.95). The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals’ FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($1.70) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The firm had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. During the same period last year, the business earned ($1.33) EPS. The company’s revenue was down 22.8% compared to the same quarter last year.

Several other equities research analysts also recently commented on the stock. Robert W. Baird cut their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. JMP Securities reiterated a “market outperform” rating and set a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $19.50.

Enanta Pharmaceuticals Trading Down 4.1 %

Shares of ENTA stock opened at $6.03 on Thursday. The firm has a market capitalization of $127.78 million, a price-to-earnings ratio of -1.11 and a beta of 0.49. The business’s 50-day moving average price is $10.33 and its 200-day moving average price is $11.96. Enanta Pharmaceuticals has a 12 month low of $6.01 and a 12 month high of $17.80.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 13.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ENTA. Barclays PLC increased its position in shares of Enanta Pharmaceuticals by 294.2% during the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 20,478 shares in the last quarter. Geode Capital Management LLC increased its holdings in Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after purchasing an additional 14,575 shares in the last quarter. Krensavage Asset Management LLC raised its stake in shares of Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after purchasing an additional 246,736 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Enanta Pharmaceuticals in the third quarter valued at approximately $360,000. Finally, State Street Corp boosted its position in shares of Enanta Pharmaceuticals by 6.4% during the third quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock valued at $4,662,000 after buying an additional 27,147 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.